ERCC1 and ovarian cancer: A study focusing on ERCC1 expression, coding for a protein involved in DNA repair and resistance to platinum compounds, in CTCs collected before debulking surgery using the AdnaTest Ovarian Cancer (QIAGEN, Germany) [72] observed that 14% of patients were CTC-positive and that ERCC1+ CTCs were associated with outcome.